Jefferies Financial Group Inc. Reduces Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Francis Steltz on May 26th, 2026

Jefferies Financial Group Inc. lowered its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 39.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,993 shares of the company’s stock after selling 67,352 shares during the quarter. Jefferies Financial Group Inc. owned about 0.17% of Structure Therapeutics worth $7,163,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State of Wyoming purchased a new position in Structure Therapeutics during the second quarter worth about $28,000. EverSource Wealth Advisors LLC boosted its stake in Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the period. CWM LLC boosted its stake in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the period. ANTIPODES PARTNERS Ltd boosted its stake in Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after buying an additional 1,146 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Structure Therapeutics during the second quarter worth about $129,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. HC Wainwright lowered their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Finally, Wolfe Research assumed coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.25.

Read Our Latest Stock Analysis on GPCR

Structure Therapeutics Stock Performance

Shares of GPCR opened at $39.19 on Tuesday. The stock has a market capitalization of $2.78 billion, a PE ratio of -45.05 and a beta of -1.31. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90. The company’s 50-day simple moving average is $46.46 and its 200-day simple moving average is $56.85.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.29 earnings per share for the current year.

Structure Therapeutics Company Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.